<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04063033</url>
  </required_header>
  <id_info>
    <org_study_id>0290-19 RMB</org_study_id>
    <nct_id>NCT04063033</nct_id>
  </id_info>
  <brief_title>IV Iron in Acute Decompensated Heart Failure</brief_title>
  <official_title>Randomized Bilnded Controlled Trial Comparing The Effect of IV Sodium Ferric Gluconate Complex (FERRLECIT R) on Outcome Patients Admitted Due To Acute Decompansated Heart Failure With Iron Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rambam Health Care Campus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims Compare the effect of addition of IV FERRLECITR (ferric gluconate) to standard&#xD;
      therapy to standard therapy alone (without any IV iron treatment) in patients admitted with&#xD;
      acute decompensated heart failure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomisation to two groups, One receiving IV Iron on top of standard therapy while admitted to the hospital and the other receiving only standard therapy for acute heart failure.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Two cardiologists will examine the participants after 12 and 24 weeks and evaluate functional status and volume status.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Functional Capacity</measure>
    <time_frame>12 and 24 Weeks</time_frame>
    <description>The functional capacity will be evaluated by the 6 minute walk test at baseline,12 weeks and 24 weeks follow up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in NYHA</measure>
    <time_frame>12 and 24 weeks</time_frame>
    <description>Change in NYHA from baseline to 12 and 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>1 Year</time_frame>
    <description>Incidence of all cause mortality up to 1 year followup</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalizations due to heart failure.</measure>
    <time_frame>1 year</time_frame>
    <description>Incidence of hospitalisations due to heart failure up to 1 year followup</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>IV Iron treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be administered IV Iron for 3-5 days. 125 mg per day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No IV Iron treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will receive standard treatment for heart failure without IV Iron.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV iron - Sodium Ferric Gluconate Complex</intervention_name>
    <description>IV Iron will be administered 125 mg each day, to 3-5 days during hospitalisation.</description>
    <arm_group_label>IV Iron treatment</arm_group_label>
    <other_name>IV Ferrlecit</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients admitted due to acute decompensated heart failure to internal medicine&#xD;
             department H or cardiology department.&#xD;
&#xD;
               -  Must meet two of the following criteria :&#xD;
&#xD;
                    -  NT pro BNP &gt; 300 pg/ml (&gt;800 pg/ml in the presence of Atrial Fibrillation).&#xD;
&#xD;
                    -  Peripheral pitting edema,&#xD;
&#xD;
                    -  Jugular Venous Distention,&#xD;
&#xD;
                    -  pulmonary edema/congestion according to physical examination or Chest X-ray.&#xD;
&#xD;
               -  IV furosemide treatment on admission to ER or internal ward/cardiology&#xD;
                  department.&#xD;
&#xD;
          2. Hb level 8-14 mg/dl on admission.&#xD;
&#xD;
          3. Iron stores: Ferritin &lt;100 or Ferritin 100-300 and Transferrin saturation &lt; 20%.&#xD;
&#xD;
          4. No evidence of active bleeding.&#xD;
&#xD;
          5. Patient provided informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Cardiogenic shock or any other condition requiring IV vasopressors.&#xD;
&#xD;
          2. Previous allergy or anaphylaxis due to IV Iron.&#xD;
&#xD;
          3. Active malignancy undergoing treatment.&#xD;
&#xD;
          4. Status post major surgery involving substantial blood loss in the past 3 months.&#xD;
&#xD;
          5. Indication for Blood transfusion.&#xD;
&#xD;
          6. Infection indicating IV antibiotics.&#xD;
&#xD;
          7. History of acquired iron overload; known haemochromatosis or first relatives with&#xD;
             hemochromatosis; and allergic disorders (asthma, eczema, and anaphylactic reactions).&#xD;
&#xD;
          8. hemolytic anemia.&#xD;
&#xD;
          9. History of chronic liver disease and/or alanine transaminase (ALT) or aspartate&#xD;
             transaminase (AST) &gt;3 times the upper limit of the normal range; chronic lung disease;&#xD;
             myelodysplastic disorder; and known HIV/AIDS disease.&#xD;
&#xD;
         10. Recipient of immunosuppressive therapy or renal dialysis. History of erythropoietin,&#xD;
             IV iron therapy, and blood transfusion in previous 30 days.&#xD;
&#xD;
         11. Unstable angina pectoris, as judged by the investigator; severe uncorrected valvular&#xD;
             disease or left ventricular outflow obstruction; obstructive cardiomyopathy;&#xD;
             uncontrolled fast atrial fibrillation or flutter (heart rate &gt;110 beats per minute&#xD;
             [bpm]); uncontrolled symptomatic brady- or tachyarrhythmias.&#xD;
&#xD;
         12. Musculoskeletal limitation that, in the judgement of the investigator, would impair&#xD;
             cardiopulmonary exercise testing.&#xD;
&#xD;
         13. Pregnant or breastfeeding.&#xD;
&#xD;
         14. Inability to comprehend study protocol.&#xD;
&#xD;
         15. Parallel participation in another clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erez Marcusohn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rambam Health Care Campus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erez Marcusohn, MD</last_name>
    <phone>972503482952</phone>
    <email>e_marcusohn@rambam.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erez Marcusohn, MD</last_name>
      <phone>972503482952</phone>
      <email>e_marcusohn@rambam.health.gov.il</email>
    </contact>
    <contact_backup>
      <last_name>Robert Zukerman, MD</last_name>
      <phone>972545401254</phone>
      <email>r_zukerman@rambam.health.gov.il</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 18, 2019</study_first_submitted>
  <study_first_submitted_qc>August 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2019</study_first_posted>
  <last_update_submitted>August 29, 2021</last_update_submitted>
  <last_update_submitted_qc>August 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rambam Health Care Campus</investigator_affiliation>
    <investigator_full_name>Erez Marcusohn MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ferric gluconate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

